Delving into the Latest Updates on Follitropin Alfa (Merck) with Synapse

Overview

Basic Info

Drug Type

Peptide Hormone

Synonyms

Follitropin alfa, Follitropin-alpha, GONAL-f

+ [17]

Target

FSHR

Action

agonists

Mechanism

FSHR agonists(Follicle-stimulating hormone receptor agonists)

Therapeutic Areas

NeoplasmsNervous System DiseasesEndocrinology and Metabolic Disease+ [1]

Active Indication

Female infertility associated with anovulationsecondary testicular failureInfertility+ [6]

Inactive Indication

AmenorrheaInfertility, Male

Originator Organization

Merck Serono SA

Active Organization

Merck Europe BVMerck Biopharma Co., Ltd.Merck Serono SA

+ [4]

Inactive Organization

Merck KGaA

Merck Serono SpA

License Organization-

Drug Highest PhaseApproved

First Approval Date

European Union (20 Oct 1995),

AnovulationFollicle stimulating hormone deficiencyHypogonadism+ [2]

Regulation-

Login to view timeline

Structure/Sequence

Sequence Code 3246

Source: *****

Sequence Code 3253

Source: *****

A Phase 1, Open Label, Randomized, 2-sequence, 2-period, Cross-over, Single Center Study to Assess the Bioequivalence of Follitropin Alfa Solution for Injection in Prefilled Pen (Test) and Follitropin Alfa Powder and Diluent for Solution for Injection in Vial (Reference) in Healthy Downregulated Male Participants

The purpose of this study is to assess the bioequivalence of Test and Reference in healthy downregulated male participants. This is a 2-sequence, 2-period study using the following treatment sequences across Study Periods 1 and 2. At the end of the first Downregulation period (DR1), eligible participants will be randomly assigned to 1 of the 2 treatment sequences:
Sequence 1: Test - Reference Sequence 2: Reference - Test Where, Test = follitropin alfa (solution for injection in prefilled pen), and Reference = follitropin alfa (powder and diluent for solution for injection in vial).
The total duration of the study will be up to approximately 9 weeks.

Start Date21 Jul 2025

Sponsor / Collaborator

EMD Serono Research & Development Institute, Inc.

[+1]

NCT06572930

/ RecruitingNot ApplicableIIT

Assessment of the Role of Serum FSH Monitoring During Ovarian Stimulation and Identification of an Optimal Range for Expected Normal Responders

This study examines if monitoring serum Follicle Stimulation Hormone (FSH) levels can predict oocyte yield and progesterone levels, considering factors like age, baseline FSH, Antral Mullerian Hormone (AMH), antral follicle count, body weight, kidney function, and urinary FSH. The aim is to find a minimum FSH level that ensures optimal ovarian response and enables tailored FSH dosages for better outcomes.

Start Date16 Dec 2024

Sponsor / Collaborator

ART Fertility Clinics LLC

NCT06571214

/ Not yet recruitingPhase 4IIT

An Exploratory, Randomized, Open-label, Controlled Study to Evaluate the Potential Benefit of r-hLH Addition in Patients Aged 35 to 40 Under Ovarian Stimulation Treatment

This will be an exploratory, prospective, randomized, open-label and controlled trial to evaluate the potential benefit of r-hFSH:r-hLH 2:1 co-treatment starting from COS D1 versus r-hFSH alone in patients aged 35 to 40 under ovarian stimulation treatment.
After signing informed consent form (ICF), all eligible participants will be randomly assigned in a 1:1 ratio to either treatment or control group, and GnRH antagonist protocol will be used in both treatment and control groups.

Start Date01 Sep 2024

Sponsor / Collaborator

Nanjing University

100 Clinical Results associated with Follitropin Alfa (Merck)

Login to view more data

100 Translational Medicine associated with Follitropin Alfa (Merck)

Login to view more data

100 Patents (Medical) associated with Follitropin Alfa (Merck)

Login to view more data

427

Literatures (Medical) associated with Follitropin Alfa (Merck)

01 Feb 2026·CLINICAL PHARMACOLOGY & THERAPEUTICS

Real‐World Effectiveness and Safety of Recombinant Human Follicle‐Stimulating Hormone (rhFSH) in Infertile Women undergoing Assisted Reproductive Technology (ART): A Korean Nationwide Cohort Study

Article

Author: Ju-Young Shin ; Ji Hyang Kim ; Hoon Kim ; Hee-Jin Seo ; Jung Ryeol Lee ; Joong Yeup Lee ; Chang-Woo Choo ; Yunju Choe ; Hyesung Lee ; Eun-Young Choi ; Yujeong Shin ; Yejin Jeon ; Young Sik Choi

Despite widespread rhFSH use in infertile women undergoing ART, real‐world comparative data on its effectiveness and safety across different rhFSH types remain limited. Using the HIRA claims database, we included 10,684 women aged 20–39 with infertility (2016–2021) who used only rhFSH in their first in vitro fertilization–embryo transfer (IVF‐ET). Outcome variables comprised effectiveness (≥ 11 oocytes retrieved, pregnancy rates and live birth rate) and safety (ectopic pregnancy, miscarriage, preterm birth and ovarian hyperstimulation syndrome [OHSS]) in the whole cohort, further categorized into follitropin and other rhFSH. Baseline characteristics were described, and relative risks (RR) with 95% confidence intervals (CI) were estimated using a generalized linear model, adjusting for age and imbalanced variables. Of 10,684 patients prescribed rhFSH, 7.1% were aged 20–29, 41.6% were 30–34, and 51.3% were 35–39. ICSI was utilized in 57.7% of cycles, and 76.8% used the GnRH antagonist protocol. The live birth rate was 38.8%, and the OHSS rate was 5.9%. Comparing baseline characteristics of the follitropin ( n = 2,594) and other rhFSH group ( n = 8,090), ICSI (62.2% vs. 56.3%) and GnRH antagonist protocol (81.3% vs. 75.3%) were more common in the follitropin group. Women who received follitropin were more likely to have ≥ 11 oocytes retrieved (adjusted RR, 1.09; 95% CI: 1.02–1.16) and less likely to have OHSS (adjusted RR, 0.73; 95% CI: 0.60–0.90). These findings provide real‐world evidence supporting rhFSH effectiveness and safety in fresh IVF cycles, with follitropin potentially offering advantages in oocyte retrieval and reduced OHSS rates.

01 Jan 2026·HUMAN REPRODUCTION

Correction to: Reply: Biosimilars versus the originator of follitropin alfa in ART: eyes wide shut?

07 Dec 2025·Cureus Journal of Medical Science

Efficacy and Safety of Folisurge, a Biosimilar Recombinant Follicle-Stimulating Hormone, Versus Gonal-F in Assisted Reproductive Technology Practice in India: A Real-World Study

Article

Author: Gupta, Nitasha ; Zaidi, Sara ; Chandra, Vipin ; Nigam, Shipra ; Sanagoudar, Shashank ; Suwalka, Isha ; Punhani, Ritu ; Mistari, Walmik ; Panday, Jyoti ; Gahalan, Anjali ; Pandey, Nihita ; Bhoi, Nihar Ranjan

OBJECTIVE:

This study was conducted to compare the efficacy and safety of Folisurge, a biosimilar recombinant follicle-stimulating hormone (r-FSH), with Gonal-f, an innovator r-FSH, in patients undergoing assisted reproductive technology (ART).

METHODS:

In this non-interventional, investigator-initiated, real-world, retrospective study, females aged 21-40 years with a body mass index (BMI) ranging between 17 and 34.9 kg/m², with serum anti-Müllerian hormone (AMH) more than 1.2 ng/mL, undergoing controlled ovarian stimulation (COS), and those having received Folisurge or Gonal-f were included. The primary outcome was the mean number of metaphase II (MII) oocytes retrieved in each group. Secondary outcomes included the mean number of embryos formed and serum β-human chorionic gonadotropin (β-hCG) positive rate in each group.

RESULTS:

A total of 3090 women were included, out of which 1210 and 1880 received Folisurge and Gonal-f, respectively. The baseline demographics were comparable in the two groups. The mean antral follicle count (AFC) was significantly higher in the Folisurge vs. the Gonal-f group (23.8 vs. 20.6, p < 0.001). Also, the mean (SD) number of oocytes retrieved was significantly higher in the Folisurge vs. the Gonal-f group (18.1 (9.4) vs. 15.5 (8.3), p < 0.001). The mean (SD) number of MII oocytes retrieved with Folisurge was significantly higher than Gonal-f (13 (7.5) vs. 10.9 (6.6), p < 0.001). Also, the mean (SD) number of embryos formed was also higher in the Folisurge vs. the Gonal-f group (4.9 (4.1) vs. 4.7 (4.1), p = 0.022). The serum β-hCG positive rate was similar between the two groups (75.5% vs. 76.2%, p = 0.667). No major safety concerns were observed in the study.

CONCLUSION:

Folisurge was comparable to Gonal-f in terms of serum β-hCG positive rate. The higher yield of oocytes and embryos in the Folisurge group should be interpreted in the context of its higher baseline AFC, which may have influenced these results. No major safety concerns were observed.

15

News (Medical) associated with Follitropin Alfa (Merck)

25 Feb 2026

·www.biospace.com

Trump Calls on Congress To Codify Most Favored Nation Drug Pricing in SOTU

White House , screengrab In his State of the Union address on Tuesday evening, President Donald Trump urged Republican leaders to pass legislation cementing his new drug pricing initiatives as he touted his efforts to lower healthcare costs for Americans. President Donald Trump called on Congress to codify his Most Favored Nation drug pricing initiative into law, as he delivered the State of the Union address at the Capitol in Washington, D.C. on Tuesday evening. He also touted his efforts to lower drug prices and the success of deals with pharma companies that were signed over the fall. “Under my just enacted Most Favored Nation agreements, Americans who have for decades paid by far the highest prices of any nation anywhere in the world for prescription drugs will now pay the lowest price anywhere in the world for drugs,” Trump said, according to a transcript of the event. “I took prescription drugs, a very big part of healthcare, from the highest price in the entire world to the lowest. That’s a big achievement.” The White House launched the TrumpRx platform in February , offering select drugs from major pharma companies on a direct-to-consumer basis. Analysts have been skeptical of the program’s ability to lower out-of-pocket costs for patients, as many of the drugs offered were heading for a patent cliff and would be lowered anyway. Other experts also questioned the impact of the program, which would likely only serve uninsured patients or those with high-deductible plans. Most patients would have access to steeper discounts via their regular insurance plans. Pfizer was the first company to sign an MFN deal last year, soon to be followed by the likes of AstraZeneca, Amgen, Bristol Myers Squibb and more. The CEOs of Eli Lilly and Novo Nordisk attended a joint announcement at the White House in November to offer their GLP-1 products, including initial doses of upcoming oral weight loss medicines, for $150. Many of the companies reached the agreements in exchange for exemption from tariffs. Drug pricing How Effective Will TrumpRx and Other Direct-to-Consumer Drug Pricing Initiatives Be? With pricing pressures climbing, Pfizer, Eli Lilly and other major drugmakers are looking to sell their products directly to patients. Analysts are skeptical that these efforts, including those announced to much fanfare from the White House, will result in meaningful reductions in drug spending. November 12, 2025 · 11 min read · Tristan Manalac Read More Trump said the TrumpRx platform has lowered drug prices “300, 400, 500, 600 percent and more.” The president specifically pointed to medicines for in vitro fertilization, which are not typically covered by insurance plans. In October, Merck KGaA’s U.S. subsidiary EMD Serono announced an agreement with the U.S. government to broaden access to its fertility medications, including Gonal-F, Ovidrel and Cetrotide. In his address, Trump called out one patient in attendance who was able to access IVF medications for less, Catherine Rayner. Rayner was the first person to utilize the TrumpRx platform, according to the president. “One drug has been costing Catherine $4,000 to purchase. But a few weeks ago, she logged on to the website and got that same drug that cost costs $4,000, got it for under $500, a reduction of much more actually than $3,500,” Trump said. “Catherine, we are all praying for you and you’re going to be a great mom.” With Rayner as an example, Trump urged his Republican leaders in Congress to codify Most Favored Nation drug pricing. “I’m not sure it matters because it’s going to be very hard for somebody that comes along after me to say, let’s raise drug prices by 700 or 800 percent. But John and Mike, if you don’t mind, codify it anyway,” he said, referring to Senate Majority Leader John Thune and House Speaker Mike Johnson. Trump already urged Congress to address MFN in a January announcement of “The Great Healthcare Plan,” which seeks to take the drug pricing fight to insurers. Drug pricing Despite MFN Deals, Drug Pricing Will Dog Pharma Into 2026 Only a handful of the top pharmas have signed Most Favored Nation drug pricing deals with the White House, while smaller biotechs continue to hang in limbo. January 6, 2026 · 5 min read · Annalee Armstrong Read More

03 Dec 2025

·www.fiercepharma.com

Workplaces labor to keep staff as fertility support falls short, Ferring survey finds

More than 20% of employees said they feel unsupported in the workplace regarding fertility treatment. A Ferring Pharmaceuticals survey has found 39% of people undergoing fertility treatment are at least considering leaving their jobs, leading the drugmaker to question whether companies are doing enough to support employees. Ferring funded the survey and worked with Fertility Matters at Work and This Can Happen, groups that offer workplace support, on the project. Having initially targeted the U.K., the survey expanded to include Australia, France, Japan and Poland and to cover more than 3,600 employees and employers. The goal was to explore how fertility challenges affect people at work and what employers can offer.Two-thirds of respondents who have faced fertility challenges said their workplaces don’t offer support for employees undergoing fertility treatment. Support is rarest in France, where 88% of respondents said their employers lacked initiatives to help workers receiving fertility treatment.The survey found 60% of respondents lacked clear entitlement to time off for fertility appointments. The situation led people undergoing fertility treatment to record time off for appointments as paid, unpaid or annual leave. Almost 20% of respondents said the lack of flexibility led them to take sick leave. The presence or absence of support is informing decisions about where to work. Beyond finding that 39% of people undergoing fertility treatment are leaving or considering quitting their jobs, the survey revealed widespread interest in roles that provide fertility support. Almost three-quarters of people who are experiencing fertility challenges would be attracted to roles that provide support.While 75% of employers said they recognize fertility treatment as a significant life event, only 27% of employees who have experienced fertility challenges agree. More than 20% of employees said they feel unsupported, and 36% have felt pressure from their employer to work while undergoing treatment or investigations. Mental well-being is a particular concern for people undergoing fertility treatment.Signs suggest uptake of fertility treatment could increase. Babies conceived using assisted reproductive technology accounted for 2.6% of births in the U.S. in 2022. The figure rises to around 10% in Denmark and 12% in Spain. President Donald Trump acted to increase access to fertility care in the U.S. in October, including by inking a drug pricing deal with Merck KGaA's EMD Serono.Like EMD Serono, Ferring sells fertility drugs. Ferring’s portfolio includes the recombinant human follicle-stimulating hormone Rekovelle, which competes with drugs including the Gonal-f product covered by Trump’s deal with EMD Serono.

20 Oct 2025

·www.pharmaceutical-technology.com

Infertility treatment heads first drugs on FDA’s new priority review scheme

Pharma companies wishing to reap the benefits of the programme need to demonstrate US-centric potential for their drug candidates. kemalbas via GettyImages. The US Food and Drug Administration (FDA) has selected the first products to be included on the Commissioner’s National Priority Voucher (CNPV) pilot programme. A total of nine drug candidates have joined the scheme launched in June 2025 , which will see its developers receive a voucher that will significantly expedite their path to approval. The group is headed by Merck’s Pergoveris (follitropin alfa/lutropin alfa), which is already approved in Europe, for the treatment of infertility. President Donald Trump specifically identified Pergoveris’ inclusion, touting the drug’s potential to offer a cheaper option to US patients. “This drug would directly compete against a much more expensive option that currently has a monopoly in the American market, and this will bring down costs very significantly,” Trump said during an IVF news conference at the White House. Trump was likely referring to Gonal-f, made by Merck’s US and Canadian healthcare business EMD Serono. Gonal-f generated global sales of €833m in 2024. The pharma company plans to use its CNPV to file for FDA approval of its new drug, which it disclosed while announcing a broader deal with the US government to expand fertility access treatment. Elsewhere on the list, candidates being developed for hearing and vision loss have been included in the form of Regeneron’s gene therapy DB-OTO and Dompé Farmaceutici’s Oxervate (cenegermin-bkbj), respectively. GlobalData Strategic Intelligence US Tariffs are shifting - will you react or anticipate? Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis. By GlobalData Learn more about Strategic Intelligence Sanofi’s teplizumab, which is already FDA-approved to delay the onset of stage 3 type 1 diabetes, has been included on the list. The agency said it was selected for “type 1 diabetes,” hinting that the review could be for a broader label approval. Revolution Therapeutics’ RMC-6236, in development for the treatment of pancreatic cancer, and Disc Medicine’s porphyria therapy bitopertin round off the list of products for specific diseases. The FDA selected cytisinicline for nicotine vaping addiction, while ketamine and Augmentin XR were chosen to boost domestic manufacturing of anaesthesia and antibiotics, respectively. The CNPV programme is the latest move by the Trump administration to bolster its pharmaceutical armoury and incentivise the development of new drugs specifically for Americans . Pharma companies wishing to reap the benefits of the programme need to demonstrate US-centric potential for their drug candidates. Therapies need to address a health crisis in the country, produce an innovative cure for American patients, meet public health needs, or increase domestic drug manufacturing as a national security issue. In its statement sharing the first batch of recipients, the FDA said that each product has significant potential to address one or more of these major national priorities. The agency stated that it would likely add another group of CNPV recipients in the coming months. Companies with a product in the programme will receive a decision within 1-2 months, compared to the usual 10-12 months, following filing of a complete application for a drug or biologic. Sponsors will also be able to undertake enhanced feedback with FDA staff during development and the review window. “One of our core goals is to deliver more cures and meaningful treatments – especially ones that have an outsized impact on our most pressing national priorities. We must modernise the review process and try new approaches to meet the needs of the American people,” said FDA commissioner Marty Makary. While the CNPV pilot begins its journey in the US regulatory landscape, experts have been concerned that its activity could take attention away from similar programmes that incentivise rare diseases. Pharmaceutical Technology Excellence Awards - The Benefits of Entering Gain the recognition you deserve! The Pharmaceutical Technology Excellence Awards celebrate innovation, leadership, and impact. By entering, you showcase your achievements, elevate your industry profile, and position yourself among top leaders driving pharmaceutical advancements. Don’t miss your chance to stand out—submit your entry today! Nominate Now

Drug ApprovalPriority Review

100 Deals associated with Follitropin Alfa (Merck)

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	G03GA05	DB00066

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Female infertility associated with anovulation	Australia	Merck Healthcare Pty Ltd.	20 Mar 2002
secondary testicular failure	Australia	Merck Healthcare Pty Ltd.	20 Mar 2002
Infertility	United States	EMD Serono, Inc.	29 Sep 1997
Anovulation	European Union	Merck Europe BV	20 Oct 1995
Anovulation	Iceland	Merck Europe BV	20 Oct 1995
Anovulation	Liechtenstein	Merck Europe BV	20 Oct 1995
Anovulation	Norway	Merck Europe BV	20 Oct 1995
Follicle stimulating hormone deficiency	European Union	Merck Europe BV	20 Oct 1995
Follicle stimulating hormone deficiency	Iceland	Merck Europe BV	20 Oct 1995
Follicle stimulating hormone deficiency	Liechtenstein	Merck Europe BV	20 Oct 1995
Follicle stimulating hormone deficiency	Norway	Merck Europe BV	20 Oct 1995
Hypogonadism	European Union	Merck Europe BV	20 Oct 1995
Hypogonadism	Iceland	Merck Europe BV	20 Oct 1995
Hypogonadism	Liechtenstein	Merck Europe BV	20 Oct 1995
Hypogonadism	Norway	Merck Europe BV	20 Oct 1995
Luteinizing hormone deficiency	European Union	Merck Europe BV	20 Oct 1995
Luteinizing hormone deficiency	Iceland	Merck Europe BV	20 Oct 1995
Luteinizing hormone deficiency	Liechtenstein	Merck Europe BV	20 Oct 1995
Luteinizing hormone deficiency	Norway	Merck Europe BV	20 Oct 1995
Polycystic Ovary Syndrome	European Union	Merck Europe BV	20 Oct 1995

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Amenorrhea	Phase 3	Japan	Merck KGaA	01 Feb 2007
Infertility, Male	Phase 2	Italy	Merck Serono SpA	14 Apr 2011
Infertility, Female	Phase 1	Netherlands	Merck Healthcare KGaA	19 Mar 2024

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05103228 (CTgov)	Not Applicable	Infertility \| Diminished ovarian reserve \| Ovarian Diseases	190	human menopausal gonadotropin+Follitropin delta+Follitropin Alfa (Lower Gonadotropin Dose Stimulation)	sizxdoicvk = elyxoljdui cvxcxdpill (shhkbogqle, jjdykqfhae - ebrrvozoww) View more	-	13 Dec 2024
				human menopausal gonadotropin+Follitropin delta+Follitropin Alfa (Higher Gonadotropin Dose Stimulation)	sizxdoicvk = aikjvwrfqc cvxcxdpill (shhkbogqle, lsofdotxhf - olbrsdirvd) View more
NCT02459418 (CTgov)	Phase 1	-	42	AFOLIA (AFOLIA)	xgvllzxibb(mcuuahyqsc) = svxndfhqsx cwsgnbinnh (yhyylmeppy, josorapnvz - qlypnykuxo) View more	-	29 May 2018
				RFF+Gonal-f (Gonal-f® RFF)	xgvllzxibb(mcuuahyqsc) = scwpoczcyk cwsgnbinnh (yhyylmeppy, wculvomnfw - nwqurvgnxb) View more
NCT01183143 (Prestyje, CTgov)	Phase 3	Infertility	215	GONAL-f®	murtavvjch = gbofpeixga jdujomffyu (oanibwjwxc, hwkdqwovyw - aizdfzqcjg) View more	-	06 Apr 2018
NCT00249834 (CONSORT, CTgov)	Phase 4	Infertility	166	Recombinant human chorionic gonadotrophin (r-hCG)+Gonal-f (Gonal-f 75 IU)	spyrajewvz(hjcpmwwrpw) = gukdioqgdx qsuypwgcfl (rqqbszqrmk, 4.5) View more	-	30 Mar 2018
				Recombinant human chorionic gonadotrophin (r-hCG)+Gonal-f (Gonal-f 112.5 IU)	spyrajewvz(hjcpmwwrpw) = ojndgorckb qsuypwgcfl (rqqbszqrmk, 6.5) View more
NCT01921166 (Diminished Ovarian Reserve, CTgov)	Phase 4	Infertility	23	Menopur+Clomid+Bravelle+Follistim+Gonal f (Clomiphene Plus Gonadotropins)	mvgpwhuoxk = dbtucfjmjw flywtlquki (inyfkfomra, tupvhrzexk - kfpnodkyak) View more	-	23 Feb 2018
				Leuprolide flare (Leuprolide Flare)	mvgpwhuoxk = xpxbsvsxpu flywtlquki (inyfkfomra, zpufqmphzc - vwwsambcng) View more
NCT02047227 (Pubmed 1 \| Pubmed 2 \| Hum Reprod)	Phase 3	-	939	r-hFSH/r-hLH	ekaeerudnx(vpjosjdbhv) = cvnxogqpbx ftderasrks (wrylgjtbfv ) View more	-	01 Mar 2017
				r-hFSH	ekaeerudnx(vpjosjdbhv) = aqoikktjrc ftderasrks (wrylgjtbfv ) View more
NCT01871532 (LoGo, CTgov)	Phase 4	Infertility \| Anovulation	24	Gonal-f (Low Dose Gonal-f)	tmpmiztvlk = wdjwoqirux vwruzgoxri (cbflhqfhks, acnrcauhbc - ssdqjqzzsc) View more	-	11 Aug 2016
				human chorionic gonadotropin (hCG)+Gonal-f (Standard Low Dose Gonal-f)	tmpmiztvlk = ouwkcryljp vwruzgoxri (cbflhqfhks, wesfevmpqj - igyamnaqfh) View more
NCT01497197 (CTgov)	Phase 3	Follicle stimulating hormone deficiency \| Infertility	174	Luveris+Gonal-f (Gonal-f®+Luveris)	zzckbtebbt(mruuctkssf) = ajlhubrnpb mcbscnfvpr (htlkxyyuoa, 6.54) View more	-	09 Nov 2015
				Luveris+Gonal-f (Gonal-f® Followed by Luveris)	zzckbtebbt(mruuctkssf) = mhmbdiaevs mcbscnfvpr (htlkxyyuoa, 5.77) View more
NCT02244866 (Pubmed \| Hum Reprod) Manual	Not Applicable	Infertility	240	Recombinant follicle-stimulating hormone +recombinant luteinizing hormone	tlyyqxqvqq(jiqeofcojo) = gydecumanm aqbmwuubqy (snztldabun )	Positive	01 May 2015
				Gonal-F	tlyyqxqvqq(jiqeofcojo) = fxmxtbrxtj aqbmwuubqy (snztldabun )
NCT00829244 (Pubmed \| Reprod Biomed Online)	Phase 4	Infertility	200	follitropin alfa (CONSORT)	idkiihjdqc(tjluvcjicr) = yoneslnxkl lkbqxrnmpw (lkwhlnjfwf )	Positive	01 Mar 2015
				follitropin alfa (Standard dosing)	idkiihjdqc(tjluvcjicr) = emahaxjstx lkbqxrnmpw (lkwhlnjfwf )

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.

login

or

view full example data

Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.

login

or

view full example data

Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.

login

or

view full example data

Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.

login

or

view full example data

Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.

login

or

view full example data

Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

login

or

view full example data

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.

login

or

view full example data

Understand key drug designations in just a few clicks with Synapse.

Follitropin Alfa (Merck)

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Biosimilar

Regulation